Table of Contents
Lymphoma
Volume 2013 (2013), Article ID 290585, 5 pages
http://dx.doi.org/10.1155/2013/290585
Research Article

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

1Department of Internal Medicine, Paul L Foster School of Medicine, Texas Tech University, 4800 Alberta Avenue, El Paso, TX 79905, USA
2Department of Pathology, Paul L Foster School of Medicine, Texas Tech University, 4800 Alberta Avenue, El Paso, TX 79905, USA

Received 3 October 2012; Accepted 16 December 2012

Academic Editor: Umberto Vitolo

Copyright © 2013 Sumit Gaur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cluster designation (CD) 20 antigen is expressed on most B-cell lymphomas and serves as a therapeutic target for rituximab. A small minority of aggressive B-cell lymphomas, predominantly plasmablastic variants, do not express CD 20. We systematically reviewed all cases of aggressive B-cell lymphomas diagnosed at our institution over a period of 13 years. Of the 232 cases, 7 did not express CD 20. Five of these were plasmablastic lymphomas while two were unclassifiable B-cell lymphomas. While most of the plasmablastic lymphomas responded to chemotherapy, patients with unclassifiable lymphomas were primarily refractory or relapsed soon after chemotherapy.